CA2594391A1 - Process for the preparation of substituted indoles - Google Patents
Process for the preparation of substituted indoles Download PDFInfo
- Publication number
- CA2594391A1 CA2594391A1 CA002594391A CA2594391A CA2594391A1 CA 2594391 A1 CA2594391 A1 CA 2594391A1 CA 002594391 A CA002594391 A CA 002594391A CA 2594391 A CA2594391 A CA 2594391A CA 2594391 A1 CA2594391 A1 CA 2594391A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compound
- process according
- methyl
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
Abstract
The invention relates to a novel process for the preparation of substituted indoles which are useful as therapeutic agents.
Description
NOVEL PROCESS
The present invention relates to a novel process for the preparation of substituted indoles which are useful as therapeutic agents.
The present invention relates to a novel process for the preparation of substituted indoles which are useful as therapeutic agents.
2 discloses a series of substituted indoles useful for the treatment of respiratory diseases.
New processes have now been developed for certain compounds which are more efficient than those disclosed in the art.
In a first aspect the invention therefore provides a process for the preparation of a io compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof:
O
ANH S; CI
N O
OH
(I) which comprises de-esterification of a compound of formula (II):
is ANH S aCI
N~ O
OR
(II) in which R is an ester forming group, and optionally thereafter forming a pharmaceutically acceptable salt or solvate.
20 The reaction can be carried out in the presence of a base followed by treatment witli acid and a ketone or ester containing solvent or mixtures of said solvents or mixtures comprising said solvents. The compounds of formula (II) are treated with a base such as an alkali metal hydroxide in a suitable solvent such as an organic alcohol, preferably at elevated temperature. The reaction mixture is then treated with acid at elevated temperature in the presence of ketone or ester-containing solvents to give the compound of formula (I). The use of ketone and ester-containing solvents has surprisingly been found to promote crystal growth. Suitable solvents include ethyl acetate, n-propylacetate and MIBK and mixtures thereof. Preferably MIBK is used. Preferably the coinpound of formula (II) is treated with aqueous sodium hydroxide in n-propanol at elevated temperature, for example at about 68 C.
Preferably the group R is phenyl, benzyl or a C1_6alkyl group such as methyl or ethyl, preferably R is C1_6alkyl, more preferably ethyl.
Compound of formula (II) are prepared by reaction of compounds of formula (III):
NO2 S aCI
N O
OR
(III) in which R is hydrogen or is as defined in formula (II) by hydrogenation followed by treatinent of the resulting ainine with an acetylating agent such as acetyl chloride. Preferably R is an ester forming group as defined in formula (II). The hydrogenation can be carried out using standard conditions such as using a platinum catalyst under a hydrogen atmosphere at is elevated pressure, e.g. a pressure of about 4 bar. This reduction can also be achieved with sodium dithionite. The resulting ainine, which is optionally isolated, for example by crystallisation from ethyl acetate/iso-hexane, is treated with acetyl chloride in a solvent such as ethyl acetate at ambient or elevated temperature, preferably at about 40 C.
Compounds of formula (III) can be prepared by reacting coinpounds of formula (IV):
S ~ ~ CI
H
(IV) with compounds of formula (V):
(V) in which R is as defined in formula (II) and X is halogen. Preferably R is ethyl and X
is bromo such that the compound (V) is ethylbromoacetate. The reaction is carried out in the presence of a base such as potassium carbonate in water/acetonitrile.
Compounds of formula (IV) can be prepared by reacting compounds of formula (VI):
N
H
(VI) with compounds of formula (VII):
RI -aS-S a R~
(VII) in wllich Rl is chloro or a group that be converted to chloro such as amino or hydrogen. Preferably R' is chloro. The reaction of compounds (VI) and (VII) can be carried out using a suitable base such as sodium methoxide in methanol at elevated temperature, or a reagent such as trichloroisocyanuric acid in a solvent such as ethyl acetate or dichlorometliane.
In an alternative einbodiment of the invention compounds of formula (II) can be prepared from compounds of formula (VIII):
O
'KNH
6:N\ 0 OR
(VIII) in which R is hydrogen or is as defined in forinula (II) by reacting with a compound of formula (VII). The reaction can be carried out using trichloroisocyanuric acid as described above. This reaction is advantageous where R is hydrogen as it can be used for the direct preparation of compounds of formula (I).
Compounds of formula (VIII) can be prepared from compounds of formula (IX):
OR
(IX) in which R is hydrogen or is as defined in formula (II) by hydrogenation and subsequent reaction of the resulting amine using analogous conditions to those described above for the hydrogenation of compound (V). Preferably R is as defined in formula (II), more preferably R is ethyl.
Compound (IX) can be prepared from a compound of formula (VI) by reaction with a compound such as ethylbromoacetate using analogous conditions to those described above for the reaction of compound (IV).
In a still further embodiment of the invention compounds of formula (III) can be prepared from compounds of formula (IX) as defined above by reacting with a compound of is fonnula (VII) as defined above using analogous conditions to those described above for the reaction of compounds (VI) a.nd (VII) using TCCA.
All novel intermediates disclosed herein form a further aspect of the invention. In a further aspect the invention therefore provides a compound of formula (VIII) and (IX).
The following examples illustrate the invention.
Example 1 3-(4-Chlorophenylsulfanyl)-2-methyl-4-nitro-lH-indole NO2 NO, S ~ ~ CI
~ \
N ~ N
New processes have now been developed for certain compounds which are more efficient than those disclosed in the art.
In a first aspect the invention therefore provides a process for the preparation of a io compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof:
O
ANH S; CI
N O
OH
(I) which comprises de-esterification of a compound of formula (II):
is ANH S aCI
N~ O
OR
(II) in which R is an ester forming group, and optionally thereafter forming a pharmaceutically acceptable salt or solvate.
20 The reaction can be carried out in the presence of a base followed by treatment witli acid and a ketone or ester containing solvent or mixtures of said solvents or mixtures comprising said solvents. The compounds of formula (II) are treated with a base such as an alkali metal hydroxide in a suitable solvent such as an organic alcohol, preferably at elevated temperature. The reaction mixture is then treated with acid at elevated temperature in the presence of ketone or ester-containing solvents to give the compound of formula (I). The use of ketone and ester-containing solvents has surprisingly been found to promote crystal growth. Suitable solvents include ethyl acetate, n-propylacetate and MIBK and mixtures thereof. Preferably MIBK is used. Preferably the coinpound of formula (II) is treated with aqueous sodium hydroxide in n-propanol at elevated temperature, for example at about 68 C.
Preferably the group R is phenyl, benzyl or a C1_6alkyl group such as methyl or ethyl, preferably R is C1_6alkyl, more preferably ethyl.
Compound of formula (II) are prepared by reaction of compounds of formula (III):
NO2 S aCI
N O
OR
(III) in which R is hydrogen or is as defined in formula (II) by hydrogenation followed by treatinent of the resulting ainine with an acetylating agent such as acetyl chloride. Preferably R is an ester forming group as defined in formula (II). The hydrogenation can be carried out using standard conditions such as using a platinum catalyst under a hydrogen atmosphere at is elevated pressure, e.g. a pressure of about 4 bar. This reduction can also be achieved with sodium dithionite. The resulting ainine, which is optionally isolated, for example by crystallisation from ethyl acetate/iso-hexane, is treated with acetyl chloride in a solvent such as ethyl acetate at ambient or elevated temperature, preferably at about 40 C.
Compounds of formula (III) can be prepared by reacting coinpounds of formula (IV):
S ~ ~ CI
H
(IV) with compounds of formula (V):
(V) in which R is as defined in formula (II) and X is halogen. Preferably R is ethyl and X
is bromo such that the compound (V) is ethylbromoacetate. The reaction is carried out in the presence of a base such as potassium carbonate in water/acetonitrile.
Compounds of formula (IV) can be prepared by reacting compounds of formula (VI):
N
H
(VI) with compounds of formula (VII):
RI -aS-S a R~
(VII) in wllich Rl is chloro or a group that be converted to chloro such as amino or hydrogen. Preferably R' is chloro. The reaction of compounds (VI) and (VII) can be carried out using a suitable base such as sodium methoxide in methanol at elevated temperature, or a reagent such as trichloroisocyanuric acid in a solvent such as ethyl acetate or dichlorometliane.
In an alternative einbodiment of the invention compounds of formula (II) can be prepared from compounds of formula (VIII):
O
'KNH
6:N\ 0 OR
(VIII) in which R is hydrogen or is as defined in forinula (II) by reacting with a compound of formula (VII). The reaction can be carried out using trichloroisocyanuric acid as described above. This reaction is advantageous where R is hydrogen as it can be used for the direct preparation of compounds of formula (I).
Compounds of formula (VIII) can be prepared from compounds of formula (IX):
OR
(IX) in which R is hydrogen or is as defined in formula (II) by hydrogenation and subsequent reaction of the resulting amine using analogous conditions to those described above for the hydrogenation of compound (V). Preferably R is as defined in formula (II), more preferably R is ethyl.
Compound (IX) can be prepared from a compound of formula (VI) by reaction with a compound such as ethylbromoacetate using analogous conditions to those described above for the reaction of compound (IV).
In a still further embodiment of the invention compounds of formula (III) can be prepared from compounds of formula (IX) as defined above by reacting with a compound of is fonnula (VII) as defined above using analogous conditions to those described above for the reaction of compounds (VI) a.nd (VII) using TCCA.
All novel intermediates disclosed herein form a further aspect of the invention. In a further aspect the invention therefore provides a compound of formula (VIII) and (IX).
The following examples illustrate the invention.
Example 1 3-(4-Chlorophenylsulfanyl)-2-methyl-4-nitro-lH-indole NO2 NO, S ~ ~ CI
~ \
N ~ N
Method A
Sodium methoxide in methanol (4.1 kg, 25% w/w, 19 mol) was added to a stirred suspension of 2-methyl-4-nitro-lH-indole (1.52 kg, 8.6 mol) and bis(p-io chlorophenyl)disulphide (2.48 kg, 8.6 mol) in methanol (6.47 kg) followed by a inethanol line rinse (0.67 kg). The mixture was then heated at 60 - 65 C for 3.5 hours.
Water (6.1 kg) was added to the reaction mixture, which was then cooled to 20 C and stirred at this temperature for 7 minutes. The solid was collected by filtration, washed with water (2 x 4 kg) followed by ethyl acetate (2 x 4 kg) then dried in a vacuum oven at 40 C. 3-(4-Chlorophenylsulfanyl)-2-methyl-4-nitro-lH-indole was obtained as a bright yellow solid, 2.57 kg (93%
yield).
1H NMR (400 MHz, D6-DMSO) 8 7.77 (d, J= 7.9 Hz, 1H), 7.63 (d, J= 7.6 Hz, 1H), 7.27 (m, 3H), 6.92 (d, J= 8.8 Hz, 2H), 2.48 (s, 3H).
LC-MS (ES+): 319 (100%, MH+).
Method B
Trichloroisocyanuric acid (450 mg, 1.9 nunol) was added to a solution of bis(p-chlorodiphenyl)disulphide (1.63 g, 5.7 mmol) in ethyl acetate (10 ml) at ambient temperature, resulting in the formation of an orange suspension. After stirring at ambient temperature for minutes, a suspension of 2-methyl-4-nitro-lH-indole (2.0 g, 11.3 mmol) in ethyl acetate 25 (10 ml) was added followed by an ethyl acetate rinse (4 ml), using water bath cooling to control the mild exotherm. Stirring was continued at ambient temperature for 40 minutes.
Aqueous sodium bicarbonate (5%, 20 ml) and water (20 ml) were added and the resulting suspension stirred at ambient temperature for 45 minutes. The solid was collected by filtration, washed with water (2 x 10 ml), followed by ethyl acetate (2 x 10 ml) then dried in a vacuum oven at 45 C to provide 3-(4-chlorophenylsulfanyl)-2-methyl-4-nitro-lH-indole, 2.9 g(81 %) as a yellow / brown solid.
L3-(4-Chlorophenylsulfanyl)-2-methyl-4-nitro-lH-indol-1-yllacetic acid, ethyl ester:
method A
NO2CI NOa S a CI
H~ -~ ~ N O
OEt 3-(4-Chlorophenylsulfanyl)-2-methyl-4-nitro-lH-indole (3.76 kg, 11.8 mol) and io potassium carbonate (1.80 kg, 13.0 mol) were suspended in acetonitrile (32.7 kg). Water (0.53 kg) and a solution of ethyl bromoacetate (2.17 kg, 13.0 mol) in acetonitrile (5.75 kg) were added followed by an acetonitrile line rinse (2.97 kg). The mixture was heated at 50 C
for 6 hours then allowed to cool to 20 C and held at this temperature overnight. Water (35.4 kg) was added to the reaction mixture and stirring continued for 30 minutes at 15 C. The solid product was collected by filtration, washed with acetonitrile (2.95 kg) then dried in a vacuum oven at 40 C to afford [3-(4-chlorophenylsulfanyl)-2-methyl-4-nitro-lH-indol-l-yl]acetic acid, ethyl ester as a bright yellow solid, 4.33 kg (91%).
1H NMR (300 MHz, D6-DMSO) 8 7.97 (dd, J= 8.3, 0.8 Hz, 1H), 7.65 (dd, J= 7.9, 0.8 Hz, 1H), 7.34 (t, J= 8.1 Hz, 1H), 7.26 (m, 2H), 6.92 (m, 2H), 5.40 (s, 2H), 4.19 (q, J= 7.0 2o Hz, 2H), 2.45 (s, 3H), 1.22 (t, J= 7.1 Hz, 3H).
LC-MS (ES+): 405 (100%, MH+), 407 (MH+).
Sodium methoxide in methanol (4.1 kg, 25% w/w, 19 mol) was added to a stirred suspension of 2-methyl-4-nitro-lH-indole (1.52 kg, 8.6 mol) and bis(p-io chlorophenyl)disulphide (2.48 kg, 8.6 mol) in methanol (6.47 kg) followed by a inethanol line rinse (0.67 kg). The mixture was then heated at 60 - 65 C for 3.5 hours.
Water (6.1 kg) was added to the reaction mixture, which was then cooled to 20 C and stirred at this temperature for 7 minutes. The solid was collected by filtration, washed with water (2 x 4 kg) followed by ethyl acetate (2 x 4 kg) then dried in a vacuum oven at 40 C. 3-(4-Chlorophenylsulfanyl)-2-methyl-4-nitro-lH-indole was obtained as a bright yellow solid, 2.57 kg (93%
yield).
1H NMR (400 MHz, D6-DMSO) 8 7.77 (d, J= 7.9 Hz, 1H), 7.63 (d, J= 7.6 Hz, 1H), 7.27 (m, 3H), 6.92 (d, J= 8.8 Hz, 2H), 2.48 (s, 3H).
LC-MS (ES+): 319 (100%, MH+).
Method B
Trichloroisocyanuric acid (450 mg, 1.9 nunol) was added to a solution of bis(p-chlorodiphenyl)disulphide (1.63 g, 5.7 mmol) in ethyl acetate (10 ml) at ambient temperature, resulting in the formation of an orange suspension. After stirring at ambient temperature for minutes, a suspension of 2-methyl-4-nitro-lH-indole (2.0 g, 11.3 mmol) in ethyl acetate 25 (10 ml) was added followed by an ethyl acetate rinse (4 ml), using water bath cooling to control the mild exotherm. Stirring was continued at ambient temperature for 40 minutes.
Aqueous sodium bicarbonate (5%, 20 ml) and water (20 ml) were added and the resulting suspension stirred at ambient temperature for 45 minutes. The solid was collected by filtration, washed with water (2 x 10 ml), followed by ethyl acetate (2 x 10 ml) then dried in a vacuum oven at 45 C to provide 3-(4-chlorophenylsulfanyl)-2-methyl-4-nitro-lH-indole, 2.9 g(81 %) as a yellow / brown solid.
L3-(4-Chlorophenylsulfanyl)-2-methyl-4-nitro-lH-indol-1-yllacetic acid, ethyl ester:
method A
NO2CI NOa S a CI
H~ -~ ~ N O
OEt 3-(4-Chlorophenylsulfanyl)-2-methyl-4-nitro-lH-indole (3.76 kg, 11.8 mol) and io potassium carbonate (1.80 kg, 13.0 mol) were suspended in acetonitrile (32.7 kg). Water (0.53 kg) and a solution of ethyl bromoacetate (2.17 kg, 13.0 mol) in acetonitrile (5.75 kg) were added followed by an acetonitrile line rinse (2.97 kg). The mixture was heated at 50 C
for 6 hours then allowed to cool to 20 C and held at this temperature overnight. Water (35.4 kg) was added to the reaction mixture and stirring continued for 30 minutes at 15 C. The solid product was collected by filtration, washed with acetonitrile (2.95 kg) then dried in a vacuum oven at 40 C to afford [3-(4-chlorophenylsulfanyl)-2-methyl-4-nitro-lH-indol-l-yl]acetic acid, ethyl ester as a bright yellow solid, 4.33 kg (91%).
1H NMR (300 MHz, D6-DMSO) 8 7.97 (dd, J= 8.3, 0.8 Hz, 1H), 7.65 (dd, J= 7.9, 0.8 Hz, 1H), 7.34 (t, J= 8.1 Hz, 1H), 7.26 (m, 2H), 6.92 (m, 2H), 5.40 (s, 2H), 4.19 (q, J= 7.0 2o Hz, 2H), 2.45 (s, 3H), 1.22 (t, J= 7.1 Hz, 3H).
LC-MS (ES+): 405 (100%, MH+), 407 (MH+).
LAcetylamino-3-(4-chlorophenylsulfanyl)-2-methyl-lH-indol-1-yll acetic acid, ethyl ester: method A
O
\2 s aCI NH2 S aCI ANH s aCI
N O N O
OEt OEt 11-4 OEt A solution of [3-(4-chlorophenylsulfanyl)-2-methyl-4-nitro-1H-indol-l-yl]acetic acid, ethyl ester (1.99 kg, 4.92 mol) in ethyl acetate (24.2 kg) was hydrogenated in the presence of a 1% Pt / C catalyst paste (1.39 kg 44% w/w) under 4 bar A hydrogen pressure.
After 2 hours hydrogen uptake had ceased so the reaction mixture was inerted then filtered through Celite io (2.60 kg). The solids were washed with ethyl acetate (3 x 8 kg) and the combined filtrates distilled until a volume of 26 L remained to leave a solution of [4-ainino-3-(4-chlorophenylsulfanyl)-2-methylindol-1-yl]acetic acid, ethyl ester in ethyl acetate. This solution was cooled to 4 C then triethylamine (0.50 kg, 4.94 mol) added, followed by an ethyl acetate line wash (0.82 kg). A solution of acetyl chloride (0.39 kg, 4.97 mol) in ethyl acetate (3 kg) was added followed by an ethyl acetate line wash (0.76 kg). The reaction mixture was heated at 40 C for 17 hours then water (16.9 kg) added. The reaction mixture was distilled down unti124.6 kg of distillate had been removed then cooled to 20 C. The solid product was collected by filtration, washed with water (1.9 kg) followed by acetonitrile (1.6 kg) then dried in a vacuum oven at 40 C to afford [4-acetylamino-3-(4-chlorophenylsulfanyl)-2-methyl-lH-indol-l-yl]acetic acid, ethyl ester, 1.69 kg (82%) as an off white solid.
1H NMR (300 MHz, DMSO) 8 9.51 (s, 1H), 7.46 (d, J= 7.5 Hz, 1H), 7.36 - 7.25 (m, 3H), 7.11 (t, J= 8.0 Hz, 1H), 6.97 (d, J= 8.7 Hz, 2H), 5.24 (s, 2H), 4.18 (q, J= 7.1 Hz, 2H), 2.39 (s, 3H), 1.86 (s, 3H), 1.21 (t, J= 7.1 Hz, 3H).
LC-MS (ES+): 417 (100%, MH+), 419 (MH+).
O
\2 s aCI NH2 S aCI ANH s aCI
N O N O
OEt OEt 11-4 OEt A solution of [3-(4-chlorophenylsulfanyl)-2-methyl-4-nitro-1H-indol-l-yl]acetic acid, ethyl ester (1.99 kg, 4.92 mol) in ethyl acetate (24.2 kg) was hydrogenated in the presence of a 1% Pt / C catalyst paste (1.39 kg 44% w/w) under 4 bar A hydrogen pressure.
After 2 hours hydrogen uptake had ceased so the reaction mixture was inerted then filtered through Celite io (2.60 kg). The solids were washed with ethyl acetate (3 x 8 kg) and the combined filtrates distilled until a volume of 26 L remained to leave a solution of [4-ainino-3-(4-chlorophenylsulfanyl)-2-methylindol-1-yl]acetic acid, ethyl ester in ethyl acetate. This solution was cooled to 4 C then triethylamine (0.50 kg, 4.94 mol) added, followed by an ethyl acetate line wash (0.82 kg). A solution of acetyl chloride (0.39 kg, 4.97 mol) in ethyl acetate (3 kg) was added followed by an ethyl acetate line wash (0.76 kg). The reaction mixture was heated at 40 C for 17 hours then water (16.9 kg) added. The reaction mixture was distilled down unti124.6 kg of distillate had been removed then cooled to 20 C. The solid product was collected by filtration, washed with water (1.9 kg) followed by acetonitrile (1.6 kg) then dried in a vacuum oven at 40 C to afford [4-acetylamino-3-(4-chlorophenylsulfanyl)-2-methyl-lH-indol-l-yl]acetic acid, ethyl ester, 1.69 kg (82%) as an off white solid.
1H NMR (300 MHz, DMSO) 8 9.51 (s, 1H), 7.46 (d, J= 7.5 Hz, 1H), 7.36 - 7.25 (m, 3H), 7.11 (t, J= 8.0 Hz, 1H), 6.97 (d, J= 8.7 Hz, 2H), 5.24 (s, 2H), 4.18 (q, J= 7.1 Hz, 2H), 2.39 (s, 3H), 1.86 (s, 3H), 1.21 (t, J= 7.1 Hz, 3H).
LC-MS (ES+): 417 (100%, MH+), 419 (MH+).
L-Acetylamino-3-(4-chlorophenylsulfanyl)-2-methyl-lH-indol-1-yllacetic Acid ANH s aCI ANH
S aCI
OEt OH
Aqueous sodium hydroxide (1 M, 11.7 kg) was added to a solution of [4-acetylamino-3-(4-chlorophenylsulfanyl)-2-methyl-1H-indol-l-yl]acetic acid, ethyl ester (2.201cg, 5.28 mol) in 1-propanol (8.2 kg) and the mixture heated to 68 C. After cooling to 40 C, the solution was filtered, the filter rinsed witll water (1 kg) then methyl isobutyl ketone (17.8 kg) was added to the filtrate, which was re-heated to 80 C. Aqueous hydrochloric acid (1 M, 12.2 kg) was added over a period of 90 minutes then the mixture cooled to 19 C. The io crystalline solid was collected by filtration, washed with water (2 x 4 kg), ethyl acetate (6 kg) then dried in a vacuum oven at 40 C to provide [4-acetylamino-3-(4-chlorophenylsulfanyl)-2-inethyl-1 1H-indol- 1 -ylacetic acid as white crystals, 1.87 kg (91%).
1H NMR (400 MHz, D6-DMSO) 8 9.51 (s, 1H), 7.47 (d, J= 7.6 Hz, 1H), 7.38 - 7.24 (m, 3H), 7.11 (t, J= 8.1 Hz, 1H), 6.98 (d, J= 8.5 Hz, 2H), 5.12 (s, 2H), 2.40 (s, 3H), 1.86 (s, 3H).
LC-MS (ES+): 389 (100%, MH ), 391 (MH+).
(4-Nitro-2-methyl-lH-indol-1-yl)-acetic acid, ethyl ester N Oz N 02 H N
~OEt Water (4.5 ml), potassium carbonate (25.9 g, 187 mmol) and ethyl bromoacetate (20.8 ml, 188 mmol) were added sequentially to a suspension of 2-methyl-4-nitro-lH-indole (30 g, 170 mmol) in acetonitrile (225 ml) and the mixture heated at 60 C for 16 hours. After allowing to cool to ambient temperature, water (225 ml) was added and the resulting mixture was broken up and then filtered. The solid was washed with water (2 x 75 ml), followed by IMS (2 x 75 ml) then dried in a vacuum oven to give (4-nitro-2-methyl-lH-indol-l-yl)-acetic acid, ethyl ester, 32.15 g (72%).
1H-NMR (300 MHz, D6-DMSO) S 8.04 (d, J= 8.1 Hz, 1H), 7.93 (d, J= 8.1 Hz, 1H), 7.27 (t, J= 8.1 Hz, 1H), 6.93 (s, 1H), 5.25 (s, 2H), 4.17 (q, J= 7.1 Hz, 2H), 2.44 (s, 3H), 1.21 (t, J= 7.1 Hz, 3H) LC-MS (ES+): 263 (100%, MH) f 3-(4-ChloroUhenylsulfanyl)-2-methyl-4-nitro-lH-indol-1-yll acetic acid, ethyl ester:
io method B
NOZ NOz S \ ~ CI
N O N O
OEt OEt Trichloroisocyanuric acid (0.30 g, 1.3 rmnol) was added to a solution of bis(p-chlorophenyl)disulphide (1.08 g, 3.8 mmol) in ethyl acetate (10 ml) at ambient temperature is resulting in formation of a yellow suspension. After stirring for 30 minutes at this temperature, a slurry of (4-nitro-2-methyl-lH-indol-1-yl)-acetic acid, ethyl ester (2.0 g, 7.6 mmol) in ethyl acetate (10 ml) was added followed by an ethyl acetate rinse (4 ml), using water bath cooling to control the mild exotherm. Stirring was continued for 35 minutes at ambient temperature. Aqueous sodium bicarbonate (5%, 20 ml) was added followed by water 20 (20 ml). After stirring for 45 minutes, ethyl acetate was removed by evaporation, the solid product collected by filtration, washed with water (2 x 10 ml), followed by 50% v/v aqueous acetonitrile (2 x 10 ml) then dried overnight in a vacuum oven at 45 C to provide [3-(4-chlorophenylsulfanyl)-2-methyl-4-nitro- 1H-indol- 1 -yl] acetic acid, ethyl ester as a bright yellow solid, 2.95 g (96%).
t4-Amino-2-methyl-lH-indol-l-yl)-acetic acid, ethyl ester N\ O N0 OEt OEt 5 A solution of (4-nitro-2-methyl-lH-indol-1-yl)-acetic acid, ethyl ester (5.0 g, 19 mmol) in ethyl acetate (75 ml) was hydrogenated under 3 bar hydrogen pressure in the presence of a wet 1% Pt / C catalyst paste (38 w/w, 0.7 g) until hydrogen uptake ceased (3 hours). The reaction mixture was filtered through kieselguhr and the solids washed with ethyl acetate (75 ml). The filtrate and wash were combined with solutions obtained from 2 io previous experiments which had been carried out in a similar maimer, each on a 2 g scale, and evaporated to dryness to provide (4-amino-2-methyl-lH-indol-1-yl)-acetic acid, ethyl ester, 8.59 g, >100% as a brown oil which solidified on standing.
1H NMR (300 MHz, D6-DMSO) S 6.73 (t, J= 7.9 Hz, 1H), 6.49 (d, J= 8.1 Hz, 1H), 6.28 (s, 1H), 6.15 (d, J= 7.5 Hz, 1H), 5.05 (br s, 2H), 4.89 (s, 2H), 4.13 (q, J= 7.1 Hz, 2H), is 2.27 (s, 3H), 1.20 (t, J= 7.1 Hz, 3H).
LC-MS (ES+): 233 (100%, MH+).
(4-Acetylamino-2-inethyl-lH-indol-1-yl)-acetic acid ethyl ester 6~N NO ~ O
~OEt OEt The (4-amino-2-methyl-lH-indol-1-yl)-acetic acid, ethyl ester prepared above (8.59 g) was dissolved in ethyl acetate (175 ml) then triethylainine (5.2 ml, 37 mmol) added followed by acetyl chloride (2.6 ml, 37 mmol). An exothenn to 35 C was observed and a thick suspension resulted. After stirring for 4 hours during which the mixture was allowed to cool back to ambient temperature, water (85 ml) was added and the ethyl acetate removed by evaporation under vacuum. The solid was collected by filtration, washed with water (25 ml) followed by 50% v/v aqueous acetonitrile (50 ml) then dried in a vacuum oven at 50 C
overnight to provide (4-acetylamino-2-methyl-lH-indol-1-yl)-acetic acid, ethyl ester, as an off-white solid, 7.26 g (77% from (4-nitro-2-methyl-lH-indol-1-yl)-acetic acid, ethyl ester).
1H NMR (300 MHz, D6-DMSO) S 9.51 (s, 1H), 7.55 (d, J= 7.7 Hz, 1H), 7.07 (d, J=
8.1 Hz, 1H), 6.96 (t, J= 7.9 Hz, 1H), 6.50 (s, 1H), 5.02 (s, 2H), 4.14 (q, J=
7.1 Hz, 2H), 2.33 (s, 3H), 2.12 (s, 3H), 1.20 (t, J= 7.1 Hz, 3H).
LC-MS (ES+): 275 (100%, MH+).
io [4-Acetylamino-3-(4-chloro-phenylsulfanyl)-2-methyl-lH-indol-l-yll -acetic acid, ethyl ester: method B
ANH ANH S CI
1~N~ 0 N\ 0 OEt OEt Trichloroisocyanuric acid (0.15 g, 0.65 mmol) was added to a solution of bis(p-chlorophenyl)disulphide (0.55 g, 1.9 mmol) in ethyl acetate (5.25 ml) at ambient temperature resulting in fonnation of a yellow suspension. After stirring for 15 minutes at this temperature, a slurry of (4-acetylamino-2-methyl- 1H-indol- 1 -yl)-acetic acid, ethyl ester (1.05 g, 3.8 mmol) in ethyl acetate (5.25 ml) was added, followed by an ethyl acetate rinse (2 ml), using water bath cooling to control the mild exotherm. Stirring was continued for lh 15 minutes at ambient temperature. Aqueous sodium bicarbonate (5%, 10.5 ml) was added followed by water (10.5 ml). After stirring for 35 minutes, the solid product was collected by filtration, washed with water (2 x 5 ml) then dried in a vacuum oven at 45 C
overnight to give [4-acetylamino-3-(4-chlorophenylsulfanyl)-2-methyl-1H-indol-l-yl]-acetic acid, ethyl ester as a grey solid, 1.13 g, 71%).
(4-Acetylamino-2-methyl-lH-indol-1-yl)acetic acid O O
ANH ANH
6~NN 0 N\ 0 OEt OH
(4-Acetylamino-2-methyl-lH-indol-1-yl)-acetic acid, ethyl ester (2.0 g, 7.3 mmol) was slurried in etllanol (10 ml) at ambient temperature. Aqueous sodium hydroxide (1 M, 10 ml, mmol) was added and the mixture heated to 50 C. The solution obtained at was then allowed to cool back to ambient temperature and aqueous hydrochloric acid (1 M, 11 ml, 11 mmol) added. The resulting solid was collected by filtration, washed with water (2 x 10 ml) io then dried in a vacuum oven at 45 C overnight to provide (4-acetylamino-2-methyl-lH-indol-1-yl)acetic acid as an off-white solid, 1.66 g (92%).
'H NMR (300 MHz, D6-DMSO) 8 12.97 (s, 1H), 9.49 (s, 1H), 7.54 (d, J= 7.5 Hz, 1H), 7.07 (d, J= 8.1 Hz, 1 H), 6.95 (t, J= 7.9 Hz, 1 H), 6.49 (s, 1H), 4.91 (s, 2H), 2.33 (d, J=
0.8 Hz, 3H), 2.12 (s, 3H) LC-MS (ES+): 247 (100%, MH+).
[4-Acetylamino-3-(4-chlorophenylsulfanyl)-2-methyl-lH-indol-1-yll acetic Acid:
method B
ANH ANH S CI
~ ~
I '~~Z \\ 1 ~ ~O N\ ~
OH O
'~ '-'~OH
Trichloroisocyanuric acid (0.13 g, 0.56 mmol) was added to a solution of bis(p-chlorophenyl)disulphide (0.47 g, 1.6 mmol) in ethyl acetate (5 ml) at ambient temperature resulting in formation of a yellow suspension. After stirring for 15 minutes at this temperature, a slurry of (4-acetylamino-2-methyl-lH-indol-1-yl)acetic acid (0.80 g, 3.2 mmol) in ethyl acetate (10 ml) was added followed by an ethyl acetate rinse (5 ml), using water bath cooling to control the mild exotherm. Stirring was continued for 1 h 15 minutes at ambient temperature. The solid product was collected by filtration, washed with ethanol (2 x s 10 ml) then dried overnight in a vacuum oven at 45 C to provide [4-acetylamino-3-(4-chlorophenylsulfanyl)-2-methyl-1H-indol-1-yl]acetic acid as an off-white solid, 1.22 g (97%).
Example 2 (2-Methyl-4-nitro-lH-indol-1-yl)acetic acid OEt OH
Aqueous sodium lzydroxide (1 M, 25 ml) was added to a solution of (4-nitro-2-inethyl-1H-indol-1-yl)acetic acid, ethyl ester (5.0 g, 18.9 mmol) in ethanol (25 ml) and the mixture is warmed to 40 C. After stirring for 70 mins at this temperature, the mixture was allowed to cool back to ambient temperature and aqueous hydrochloric acid (1 M, 27.5 ml) added causing precipitation of a solid. This was collected by filtration, washed with water (2 x 25 ml) then dried in a vacuum oven at 50 C overnight to leave (2-methyl-4-nitro-1H-indol-1-yl)acetic acid as a yellow solid, 4.18 g (94%).
'H-NMR (300 MHz, D6-DMSO) S 13.2 (s, 1H), 8.03 (d, J= 8.1 Hz, 1H), 7.93 (d, J=
8.1 Hz, 1H), 7.26 (t, J= 8.1 Hz, 1 H), 6.92 (s, 1H), 5.13 (s, 2H), 2.45 (s, 3H) LC-MS (ES+): 235 (100%, MH) f3-(4-Chlorophenylsulfanyl)-2-methyl-4-nitro-lH-indol-1-yllacetic acid NO~ NOZ S a CI
OH OH
Trichloroisocyanuric acid (0.51 g, 2.2 mmol) was added to a solution of bis(p-chlorophenyl)disulphide (1.84 g, 6.4 minol) in ethyl acetate (15 ml) at ambient temperature resulting in formation of a yellow suspension. After stirring for 5 minutes at this temperature, a slurry of (4-nitro-2-methyl-lH-indol-1-yl)-acetic acid (3.0 g, 12.8 mmol) in ethyl acetate (30 ml) was added followed by an ethyl acetate rinse (6 ml). Stirring was continued for 40 io minutes at ambient temperature. The solid product was collected by filtration, washed with ethyl acetate (2 x 10 ml) then dried overnight in a vacuum oven at 50 C to provide [3-(4-chlorophenylsulfanyl)-2-methyl-4-nitro-1Hindol-1-yl]acetic acid as a bright yellow solid, 2.93 g. The by-product, cyanuric acid, was not removed during the work up.
1H NMR (300 MHz, D6-DMSO) S 13.4 (s, 1H), 7.97 (dd, J= 8.3, 0.8 Hz, 1H), 7.64 (dd, J= 7.7, 0.8 Hz, 1H), 7.34 (t, J= 8.1 Hz, 1H), 7.25 (m, 2H), 6.92 (m, 2H), 5.28 (s, 2H), 2.45 (s, 3H).
LC-MS (ES+): 377 (100%, MH+), 379 (MH+).
The product can be converted to a coinpound of formula (I) by reduction of the nitro group followed by amide formation using a process analogous to that given above for [4-2o Acetylamino-3 -(4-chlorophenylsulfanyl)-2-methyl- 1H-indol- 1 -yl] acetic acid, ethyl ester:
method A
S aCI
OEt OH
Aqueous sodium hydroxide (1 M, 11.7 kg) was added to a solution of [4-acetylamino-3-(4-chlorophenylsulfanyl)-2-methyl-1H-indol-l-yl]acetic acid, ethyl ester (2.201cg, 5.28 mol) in 1-propanol (8.2 kg) and the mixture heated to 68 C. After cooling to 40 C, the solution was filtered, the filter rinsed witll water (1 kg) then methyl isobutyl ketone (17.8 kg) was added to the filtrate, which was re-heated to 80 C. Aqueous hydrochloric acid (1 M, 12.2 kg) was added over a period of 90 minutes then the mixture cooled to 19 C. The io crystalline solid was collected by filtration, washed with water (2 x 4 kg), ethyl acetate (6 kg) then dried in a vacuum oven at 40 C to provide [4-acetylamino-3-(4-chlorophenylsulfanyl)-2-inethyl-1 1H-indol- 1 -ylacetic acid as white crystals, 1.87 kg (91%).
1H NMR (400 MHz, D6-DMSO) 8 9.51 (s, 1H), 7.47 (d, J= 7.6 Hz, 1H), 7.38 - 7.24 (m, 3H), 7.11 (t, J= 8.1 Hz, 1H), 6.98 (d, J= 8.5 Hz, 2H), 5.12 (s, 2H), 2.40 (s, 3H), 1.86 (s, 3H).
LC-MS (ES+): 389 (100%, MH ), 391 (MH+).
(4-Nitro-2-methyl-lH-indol-1-yl)-acetic acid, ethyl ester N Oz N 02 H N
~OEt Water (4.5 ml), potassium carbonate (25.9 g, 187 mmol) and ethyl bromoacetate (20.8 ml, 188 mmol) were added sequentially to a suspension of 2-methyl-4-nitro-lH-indole (30 g, 170 mmol) in acetonitrile (225 ml) and the mixture heated at 60 C for 16 hours. After allowing to cool to ambient temperature, water (225 ml) was added and the resulting mixture was broken up and then filtered. The solid was washed with water (2 x 75 ml), followed by IMS (2 x 75 ml) then dried in a vacuum oven to give (4-nitro-2-methyl-lH-indol-l-yl)-acetic acid, ethyl ester, 32.15 g (72%).
1H-NMR (300 MHz, D6-DMSO) S 8.04 (d, J= 8.1 Hz, 1H), 7.93 (d, J= 8.1 Hz, 1H), 7.27 (t, J= 8.1 Hz, 1H), 6.93 (s, 1H), 5.25 (s, 2H), 4.17 (q, J= 7.1 Hz, 2H), 2.44 (s, 3H), 1.21 (t, J= 7.1 Hz, 3H) LC-MS (ES+): 263 (100%, MH) f 3-(4-ChloroUhenylsulfanyl)-2-methyl-4-nitro-lH-indol-1-yll acetic acid, ethyl ester:
io method B
NOZ NOz S \ ~ CI
N O N O
OEt OEt Trichloroisocyanuric acid (0.30 g, 1.3 rmnol) was added to a solution of bis(p-chlorophenyl)disulphide (1.08 g, 3.8 mmol) in ethyl acetate (10 ml) at ambient temperature is resulting in formation of a yellow suspension. After stirring for 30 minutes at this temperature, a slurry of (4-nitro-2-methyl-lH-indol-1-yl)-acetic acid, ethyl ester (2.0 g, 7.6 mmol) in ethyl acetate (10 ml) was added followed by an ethyl acetate rinse (4 ml), using water bath cooling to control the mild exotherm. Stirring was continued for 35 minutes at ambient temperature. Aqueous sodium bicarbonate (5%, 20 ml) was added followed by water 20 (20 ml). After stirring for 45 minutes, ethyl acetate was removed by evaporation, the solid product collected by filtration, washed with water (2 x 10 ml), followed by 50% v/v aqueous acetonitrile (2 x 10 ml) then dried overnight in a vacuum oven at 45 C to provide [3-(4-chlorophenylsulfanyl)-2-methyl-4-nitro- 1H-indol- 1 -yl] acetic acid, ethyl ester as a bright yellow solid, 2.95 g (96%).
t4-Amino-2-methyl-lH-indol-l-yl)-acetic acid, ethyl ester N\ O N0 OEt OEt 5 A solution of (4-nitro-2-methyl-lH-indol-1-yl)-acetic acid, ethyl ester (5.0 g, 19 mmol) in ethyl acetate (75 ml) was hydrogenated under 3 bar hydrogen pressure in the presence of a wet 1% Pt / C catalyst paste (38 w/w, 0.7 g) until hydrogen uptake ceased (3 hours). The reaction mixture was filtered through kieselguhr and the solids washed with ethyl acetate (75 ml). The filtrate and wash were combined with solutions obtained from 2 io previous experiments which had been carried out in a similar maimer, each on a 2 g scale, and evaporated to dryness to provide (4-amino-2-methyl-lH-indol-1-yl)-acetic acid, ethyl ester, 8.59 g, >100% as a brown oil which solidified on standing.
1H NMR (300 MHz, D6-DMSO) S 6.73 (t, J= 7.9 Hz, 1H), 6.49 (d, J= 8.1 Hz, 1H), 6.28 (s, 1H), 6.15 (d, J= 7.5 Hz, 1H), 5.05 (br s, 2H), 4.89 (s, 2H), 4.13 (q, J= 7.1 Hz, 2H), is 2.27 (s, 3H), 1.20 (t, J= 7.1 Hz, 3H).
LC-MS (ES+): 233 (100%, MH+).
(4-Acetylamino-2-inethyl-lH-indol-1-yl)-acetic acid ethyl ester 6~N NO ~ O
~OEt OEt The (4-amino-2-methyl-lH-indol-1-yl)-acetic acid, ethyl ester prepared above (8.59 g) was dissolved in ethyl acetate (175 ml) then triethylainine (5.2 ml, 37 mmol) added followed by acetyl chloride (2.6 ml, 37 mmol). An exothenn to 35 C was observed and a thick suspension resulted. After stirring for 4 hours during which the mixture was allowed to cool back to ambient temperature, water (85 ml) was added and the ethyl acetate removed by evaporation under vacuum. The solid was collected by filtration, washed with water (25 ml) followed by 50% v/v aqueous acetonitrile (50 ml) then dried in a vacuum oven at 50 C
overnight to provide (4-acetylamino-2-methyl-lH-indol-1-yl)-acetic acid, ethyl ester, as an off-white solid, 7.26 g (77% from (4-nitro-2-methyl-lH-indol-1-yl)-acetic acid, ethyl ester).
1H NMR (300 MHz, D6-DMSO) S 9.51 (s, 1H), 7.55 (d, J= 7.7 Hz, 1H), 7.07 (d, J=
8.1 Hz, 1H), 6.96 (t, J= 7.9 Hz, 1H), 6.50 (s, 1H), 5.02 (s, 2H), 4.14 (q, J=
7.1 Hz, 2H), 2.33 (s, 3H), 2.12 (s, 3H), 1.20 (t, J= 7.1 Hz, 3H).
LC-MS (ES+): 275 (100%, MH+).
io [4-Acetylamino-3-(4-chloro-phenylsulfanyl)-2-methyl-lH-indol-l-yll -acetic acid, ethyl ester: method B
ANH ANH S CI
1~N~ 0 N\ 0 OEt OEt Trichloroisocyanuric acid (0.15 g, 0.65 mmol) was added to a solution of bis(p-chlorophenyl)disulphide (0.55 g, 1.9 mmol) in ethyl acetate (5.25 ml) at ambient temperature resulting in fonnation of a yellow suspension. After stirring for 15 minutes at this temperature, a slurry of (4-acetylamino-2-methyl- 1H-indol- 1 -yl)-acetic acid, ethyl ester (1.05 g, 3.8 mmol) in ethyl acetate (5.25 ml) was added, followed by an ethyl acetate rinse (2 ml), using water bath cooling to control the mild exotherm. Stirring was continued for lh 15 minutes at ambient temperature. Aqueous sodium bicarbonate (5%, 10.5 ml) was added followed by water (10.5 ml). After stirring for 35 minutes, the solid product was collected by filtration, washed with water (2 x 5 ml) then dried in a vacuum oven at 45 C
overnight to give [4-acetylamino-3-(4-chlorophenylsulfanyl)-2-methyl-1H-indol-l-yl]-acetic acid, ethyl ester as a grey solid, 1.13 g, 71%).
(4-Acetylamino-2-methyl-lH-indol-1-yl)acetic acid O O
ANH ANH
6~NN 0 N\ 0 OEt OH
(4-Acetylamino-2-methyl-lH-indol-1-yl)-acetic acid, ethyl ester (2.0 g, 7.3 mmol) was slurried in etllanol (10 ml) at ambient temperature. Aqueous sodium hydroxide (1 M, 10 ml, mmol) was added and the mixture heated to 50 C. The solution obtained at was then allowed to cool back to ambient temperature and aqueous hydrochloric acid (1 M, 11 ml, 11 mmol) added. The resulting solid was collected by filtration, washed with water (2 x 10 ml) io then dried in a vacuum oven at 45 C overnight to provide (4-acetylamino-2-methyl-lH-indol-1-yl)acetic acid as an off-white solid, 1.66 g (92%).
'H NMR (300 MHz, D6-DMSO) 8 12.97 (s, 1H), 9.49 (s, 1H), 7.54 (d, J= 7.5 Hz, 1H), 7.07 (d, J= 8.1 Hz, 1 H), 6.95 (t, J= 7.9 Hz, 1 H), 6.49 (s, 1H), 4.91 (s, 2H), 2.33 (d, J=
0.8 Hz, 3H), 2.12 (s, 3H) LC-MS (ES+): 247 (100%, MH+).
[4-Acetylamino-3-(4-chlorophenylsulfanyl)-2-methyl-lH-indol-1-yll acetic Acid:
method B
ANH ANH S CI
~ ~
I '~~Z \\ 1 ~ ~O N\ ~
OH O
'~ '-'~OH
Trichloroisocyanuric acid (0.13 g, 0.56 mmol) was added to a solution of bis(p-chlorophenyl)disulphide (0.47 g, 1.6 mmol) in ethyl acetate (5 ml) at ambient temperature resulting in formation of a yellow suspension. After stirring for 15 minutes at this temperature, a slurry of (4-acetylamino-2-methyl-lH-indol-1-yl)acetic acid (0.80 g, 3.2 mmol) in ethyl acetate (10 ml) was added followed by an ethyl acetate rinse (5 ml), using water bath cooling to control the mild exotherm. Stirring was continued for 1 h 15 minutes at ambient temperature. The solid product was collected by filtration, washed with ethanol (2 x s 10 ml) then dried overnight in a vacuum oven at 45 C to provide [4-acetylamino-3-(4-chlorophenylsulfanyl)-2-methyl-1H-indol-1-yl]acetic acid as an off-white solid, 1.22 g (97%).
Example 2 (2-Methyl-4-nitro-lH-indol-1-yl)acetic acid OEt OH
Aqueous sodium lzydroxide (1 M, 25 ml) was added to a solution of (4-nitro-2-inethyl-1H-indol-1-yl)acetic acid, ethyl ester (5.0 g, 18.9 mmol) in ethanol (25 ml) and the mixture is warmed to 40 C. After stirring for 70 mins at this temperature, the mixture was allowed to cool back to ambient temperature and aqueous hydrochloric acid (1 M, 27.5 ml) added causing precipitation of a solid. This was collected by filtration, washed with water (2 x 25 ml) then dried in a vacuum oven at 50 C overnight to leave (2-methyl-4-nitro-1H-indol-1-yl)acetic acid as a yellow solid, 4.18 g (94%).
'H-NMR (300 MHz, D6-DMSO) S 13.2 (s, 1H), 8.03 (d, J= 8.1 Hz, 1H), 7.93 (d, J=
8.1 Hz, 1H), 7.26 (t, J= 8.1 Hz, 1 H), 6.92 (s, 1H), 5.13 (s, 2H), 2.45 (s, 3H) LC-MS (ES+): 235 (100%, MH) f3-(4-Chlorophenylsulfanyl)-2-methyl-4-nitro-lH-indol-1-yllacetic acid NO~ NOZ S a CI
OH OH
Trichloroisocyanuric acid (0.51 g, 2.2 mmol) was added to a solution of bis(p-chlorophenyl)disulphide (1.84 g, 6.4 minol) in ethyl acetate (15 ml) at ambient temperature resulting in formation of a yellow suspension. After stirring for 5 minutes at this temperature, a slurry of (4-nitro-2-methyl-lH-indol-1-yl)-acetic acid (3.0 g, 12.8 mmol) in ethyl acetate (30 ml) was added followed by an ethyl acetate rinse (6 ml). Stirring was continued for 40 io minutes at ambient temperature. The solid product was collected by filtration, washed with ethyl acetate (2 x 10 ml) then dried overnight in a vacuum oven at 50 C to provide [3-(4-chlorophenylsulfanyl)-2-methyl-4-nitro-1Hindol-1-yl]acetic acid as a bright yellow solid, 2.93 g. The by-product, cyanuric acid, was not removed during the work up.
1H NMR (300 MHz, D6-DMSO) S 13.4 (s, 1H), 7.97 (dd, J= 8.3, 0.8 Hz, 1H), 7.64 (dd, J= 7.7, 0.8 Hz, 1H), 7.34 (t, J= 8.1 Hz, 1H), 7.25 (m, 2H), 6.92 (m, 2H), 5.28 (s, 2H), 2.45 (s, 3H).
LC-MS (ES+): 377 (100%, MH+), 379 (MH+).
The product can be converted to a coinpound of formula (I) by reduction of the nitro group followed by amide formation using a process analogous to that given above for [4-2o Acetylamino-3 -(4-chlorophenylsulfanyl)-2-methyl- 1H-indol- 1 -yl] acetic acid, ethyl ester:
method A
Claims (15)
1. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof:
which comprises de-esterification of a compound of formula (II):
in which R is an ester forming group, in the presence of a base followed by treatment with an acid and a ketone or ester containing solvent, and optionally thereafter forming a pharmaceutically acceptable salt or solvate.
which comprises de-esterification of a compound of formula (II):
in which R is an ester forming group, in the presence of a base followed by treatment with an acid and a ketone or ester containing solvent, and optionally thereafter forming a pharmaceutically acceptable salt or solvate.
2. A process according to claim 1 in which R is C1-6alkyl.
3. A process according to claim 1 or 2 in which R is ethyl.
4. A process according to any one of claims 1 to 3 which is carried out using an alkali metal hydroxide in an organic alcohol solvent.
5. A process according to any one of claims 1 to 4 which is carried out using aqueous sodium hydroxide in n-propanol.
6. A process according to any one of claims 1 to 5 which is carried out at a temperature of about 68°C.
7. A process according to any one of claims 1 to 5 in which the acid treatment is carried out in the presence of ethyl acetate, n-propylacetate and MIBK and mixtures thereof.
8. A process according to any one of claims 1 to 5 which the acid treatment is carried out in the presence of MIBK.
9. A compound of formula (I) prepared using the process according to any one of claims 1 to 8.
10. A process for the preparation of a compound of formula (I) or (II) which comprises reaction of a compound of formula (VIII):
in which R is hydrogen or is as defined in formula (II) by reacting with a compound of formula (VII).
in which R1 is chloro or a group that can be converted to chloro, and optionally thereafter forming a pharmaceutically acceptable salt or solvate.
in which R is hydrogen or is as defined in formula (II) by reacting with a compound of formula (VII).
in which R1 is chloro or a group that can be converted to chloro, and optionally thereafter forming a pharmaceutically acceptable salt or solvate.
11. A process for the preparation of a compound of formula (II) or the corresponding carboxylic acid which comprises reducing a compound of formula (III):
in which R is hydrogen or is as defined in formula (II) with sodium dithionite or by hydrogenation followed by amide formation.
in which R is hydrogen or is as defined in formula (II) with sodium dithionite or by hydrogenation followed by amide formation.
12. A process for the preparation of a compound of formula (III) or the corresponding carboxylic acid which comprises reaction of a compound of formula (IX):
in which R is hydrogen or is as defined in formula (II) with a compound of formula (VII):
in which R1 is chloro or a group that can be converted to chloro.
in which R is hydrogen or is as defined in formula (II) with a compound of formula (VII):
in which R1 is chloro or a group that can be converted to chloro.
13. A process for the preparation of compounds of formula (IV) by reacting compounds of formula (VI):
with compounds of formula (VII):
in which R1 is chloro or a group that can be converted to chloro.
with compounds of formula (VII):
in which R1 is chloro or a group that can be converted to chloro.
14. A compound of formula (VIII):
in which R is hydrogen, phenyl, benzyl or C1--6 alkyl.
in which R is hydrogen, phenyl, benzyl or C1--6 alkyl.
15. A compound of formula (IX):
in which R is hydrogen, phenyl, benzyl or C1-6 alkyl.
in which R is hydrogen, phenyl, benzyl or C1-6 alkyl.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0500604.4 | 2005-01-13 | ||
| GBGB0500604.4A GB0500604D0 (en) | 2005-01-13 | 2005-01-13 | Novel process |
| PCT/GB2006/000060 WO2006075139A2 (en) | 2005-01-13 | 2006-01-09 | Novel process for the preparation of substituted indoles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2594391A1 true CA2594391A1 (en) | 2006-07-20 |
Family
ID=34203986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002594391A Abandoned CA2594391A1 (en) | 2005-01-13 | 2006-01-09 | Process for the preparation of substituted indoles |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7781598B2 (en) |
| EP (1) | EP1844012A2 (en) |
| JP (1) | JP2008526936A (en) |
| KR (1) | KR20070104350A (en) |
| CN (1) | CN101102999B (en) |
| AU (1) | AU2006205697B2 (en) |
| BR (1) | BRPI0606639A2 (en) |
| CA (1) | CA2594391A1 (en) |
| GB (1) | GB0500604D0 (en) |
| IL (1) | IL183965A0 (en) |
| MX (1) | MX2007008348A (en) |
| NO (1) | NO20074047L (en) |
| NZ (1) | NZ556147A (en) |
| WO (1) | WO2006075139A2 (en) |
| ZA (1) | ZA200705216B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (en) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| SE0301569D0 (en) * | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| SE0302232D0 (en) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| SE0303180D0 (en) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| GB0500604D0 (en) | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
| WO2007138282A2 (en) * | 2006-05-26 | 2007-12-06 | Astrazeneca Ab | Bi-aryl or aryl-heteroaryl substituted indoles |
| CA2767132C (en) * | 2009-07-06 | 2017-06-20 | Astrazeneca Ab | Intermediates and processes for the preparation of 4-(acetylamino))-3-[(4-chloro-phenyl)thio]-2-methyl-1h-indole-1-acetic acid |
| US20140328861A1 (en) | 2011-12-16 | 2014-11-06 | Atopix Therapeutics Limited | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis |
| CN103288707B (en) * | 2013-05-28 | 2015-12-23 | 浙江大学 | A kind of preparation method of 3-benzene sulfydryl indole derivative |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE790679A (en) | 1971-11-03 | 1973-04-27 | Ici Ltd | INDOLE DERIVATIVES |
| JPH0615542B2 (en) | 1986-07-22 | 1994-03-02 | 吉富製薬株式会社 | Pyrazolopyridine compound |
| US5095031A (en) * | 1990-08-20 | 1992-03-10 | Abbott Laboratories | Indole derivatives which inhibit leukotriene biosynthesis |
| WO1993005020A1 (en) | 1991-09-06 | 1993-03-18 | Merck & Co., Inc. | Indoles as inhibitors of hiv reverse transcriptase |
| FR2692574B1 (en) | 1992-06-23 | 1995-06-23 | Sanofi Elf | 4-HYDROXY BENZENETHIO DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR THE PREPARATION OF AMINOALKOXYBENZENESULFONYL DERIVATIVES. |
| HUT74614A (en) | 1993-02-24 | 1997-01-28 | Merck & Co Inc | Nindol derivates suitable for treatment of infection by hiv and pharmaceutical compositions containing them |
| US5486525A (en) * | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
| US5567711A (en) * | 1995-04-19 | 1996-10-22 | Abbott Laboratories | Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists |
| TW472045B (en) | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
| AR017256A1 (en) | 1997-08-21 | 2001-09-05 | American Home Prod | INDOL SUBSTITUTED COMPOUNDS, METHOD FOR SOLID PHASE SYNTHESIS OF THE SAME, COMBINATION SETS TO BE EMPLOYED IN THAT METHOD, USE OF COMPOUNDS TO PREPARE A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM |
| ZA9811672B (en) | 1997-12-19 | 2000-06-19 | Lilly Co Eli | Hypoglycemic imidazoline compounds. |
| US6916841B2 (en) * | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| AU5886500A (en) | 1999-06-23 | 2001-01-09 | Sepracor, Inc. | Indolyl-benzimidazole antibacterials, and methods of use thereof |
| WO2001032621A1 (en) | 1999-10-29 | 2001-05-10 | Wakunaga Pharmaceutical Co., Ltd. | Novel indole derivatives and drugs containing the same as the active ingredient |
| CA2395593C (en) | 1999-12-24 | 2011-08-02 | Aventis Pharma Limited | Azaindoles |
| BR0111230A (en) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Compound, and, use and process for the preparation thereof |
| US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| WO2003013510A1 (en) * | 2001-08-07 | 2003-02-20 | Smithkline Beecham P.L.C. | 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
| TWI317634B (en) * | 2001-12-13 | 2009-12-01 | Nat Health Research Institutes | Aroyl indoles compounds |
| AU2003218962B2 (en) | 2002-02-01 | 2008-09-25 | F. Hoffmann-La Roche Ag | Substituted indoles as alpha-1 agonists |
| SE0200356D0 (en) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200411D0 (en) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| EP1505061A4 (en) | 2002-05-16 | 2007-08-22 | Shionogi & Co | Compound exhibiting pgd 2 receptor antagonism |
| TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0201635D0 (en) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (en) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| SE0202463D0 (en) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| DE60334015D1 (en) * | 2002-10-30 | 2010-10-14 | Merck Frosst Canada Ltd | PYRIDOPYRROLIZIN AND PYRIDOINDOLIZIN DERIVATIVES |
| DE60316180T2 (en) * | 2002-12-03 | 2008-05-29 | F. Hoffmann-La Roche Ag | AMINOALKOXYINDOL DERIVATIVES AS 5-HT6 RECEPTOR LIGANDS FOR COMBATING CNS DISEASES |
| SE0301569D0 (en) * | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| SE0302232D0 (en) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| RU2006109108A (en) | 2003-10-14 | 2007-11-20 | Оксаген Лимитед (GB) | COMPOUNDS POSSESSING THE ACTIVITY OF CRTH2 RECEPTOR ANTAGONISTS |
| SE0303180D0 (en) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| GB0500604D0 (en) | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
| GB2422831A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
| WO2007138282A2 (en) | 2006-05-26 | 2007-12-06 | Astrazeneca Ab | Bi-aryl or aryl-heteroaryl substituted indoles |
| JP2009539782A (en) | 2006-06-08 | 2009-11-19 | ニューロキー エイ／エス | How to use hypothermia-inducing drugs |
| MX2008015768A (en) | 2006-06-28 | 2009-01-07 | Sanofi Aventis | New cxcr2 inhibitors. |
-
2005
- 2005-01-13 GB GBGB0500604.4A patent/GB0500604D0/en not_active Ceased
-
2006
- 2006-01-09 AU AU2006205697A patent/AU2006205697B2/en not_active Ceased
- 2006-01-09 JP JP2007550831A patent/JP2008526936A/en active Pending
- 2006-01-09 BR BRPI0606639-9A patent/BRPI0606639A2/en not_active IP Right Cessation
- 2006-01-09 MX MX2007008348A patent/MX2007008348A/en active IP Right Grant
- 2006-01-09 CN CN2006800023115A patent/CN101102999B/en not_active Expired - Fee Related
- 2006-01-09 WO PCT/GB2006/000060 patent/WO2006075139A2/en active Application Filing
- 2006-01-09 CA CA002594391A patent/CA2594391A1/en not_active Abandoned
- 2006-01-09 US US11/813,816 patent/US7781598B2/en not_active Expired - Fee Related
- 2006-01-09 NZ NZ556147A patent/NZ556147A/en not_active IP Right Cessation
- 2006-01-09 KR KR1020077015946A patent/KR20070104350A/en not_active Application Discontinuation
- 2006-01-09 EP EP06700281A patent/EP1844012A2/en not_active Withdrawn
-
2007
- 2007-06-14 IL IL183965A patent/IL183965A0/en unknown
- 2007-06-29 ZA ZA200705216A patent/ZA200705216B/en unknown
- 2007-08-06 NO NO20074047A patent/NO20074047L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1844012A2 (en) | 2007-10-17 |
| IL183965A0 (en) | 2007-10-31 |
| US7781598B2 (en) | 2010-08-24 |
| GB0500604D0 (en) | 2005-02-16 |
| NO20074047L (en) | 2007-08-06 |
| KR20070104350A (en) | 2007-10-25 |
| WO2006075139A2 (en) | 2006-07-20 |
| JP2008526936A (en) | 2008-07-24 |
| ZA200705216B (en) | 2008-09-25 |
| BRPI0606639A2 (en) | 2009-07-07 |
| CN101102999B (en) | 2010-12-29 |
| AU2006205697A1 (en) | 2006-07-20 |
| AU2006205697B2 (en) | 2009-01-22 |
| WO2006075139A3 (en) | 2006-10-19 |
| CN101102999A (en) | 2008-01-09 |
| MX2007008348A (en) | 2007-08-03 |
| US20080051586A1 (en) | 2008-02-28 |
| NZ556147A (en) | 2010-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2594391A1 (en) | Process for the preparation of substituted indoles | |
| US7906677B2 (en) | Process for phenylacetic acid derivatives | |
| EP2118058B1 (en) | Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole | |
| US7582771B2 (en) | Process for the synthesis of cPLA2 inhibitors | |
| HU225459B1 (en) | Process for preparing substituted imidazopyridine compound | |
| WO2010049952A2 (en) | A novel process for the preparation of 5-substituted indole derivatives | |
| US4550165A (en) | Process for producing 1,2,5,6-tetrahydro-4H-pyrrolo-[3,2,1-ij]-quinolin-4-one | |
| JPH10195064A (en) | Production of 5-amino-1,2,4-thiadiazoleacetic acid derivative (syn-isomer) | |
| HU199414B (en) | Process for producing substituted indolinone derivatives | |
| JP3572668B2 (en) | Method for producing acylaminophthalic acid derivative | |
| US4595755A (en) | 5-halo-1,2,3-(1,2-dihydropyrrolo)-4-quinolones | |
| JP2005533037A (en) | Process for preparing (S) -tetrahydro-α- (1-methylethyl) -2-oxo-1 (2H) -pyrimidineacetic acid | |
| US6423849B1 (en) | Process of preparing 5-(2-substituted-4-nitrophenyl)-oxazole, novel oxazole compound, and process of preparing the same | |
| SK13592001A3 (en) | Synthesis of 3-amino-3-aryl propanoates | |
| US20120190849A1 (en) | Processes for the preparation of vardenafil | |
| JP3832980B2 (en) | A novel intermediate for the production of tetrahydrofuranyl derivatives with insecticidal activity | |
| JP2536756B2 (en) | 5-alkoxyanthranilic acid ester | |
| JPWO2005063678A1 (en) | Method for producing phenylacetic acid derivative | |
| CN114105961A (en) | Preparation method of IDO1 inhibitor (LY-3381916) | |
| JP2001302611A (en) | Method for producing 5-trifluoromethyldihydrouracil | |
| JPS6145622B2 (en) | ||
| SK41297A3 (en) | Method for preparing nitrobenzene derivatives | |
| SK19452000A3 (en) | Process for the dehalogenation of thiochroman and dihydrobenzothiophene derivatives | |
| JPH08269048A (en) | Production of benzoimidazole derivative | |
| JPH08143539A (en) | Anilide derivative and its production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20140812 |